nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolterodine—Bromodiphenhydramine—Tamoxifen—pancreatic cancer	0.28	0.56	CrCrCtD
Tolterodine—Orphenadrine—Tamoxifen—pancreatic cancer	0.22	0.44	CrCrCtD
Tolterodine—KCNH2—Sunitinib—pancreatic cancer	0.0713	0.227	CbGbCtD
Tolterodine—CYP2C19—Tamoxifen—pancreatic cancer	0.0394	0.125	CbGbCtD
Tolterodine—CYP2C9—Tamoxifen—pancreatic cancer	0.0327	0.104	CbGbCtD
Tolterodine—CYP2D6—Tamoxifen—pancreatic cancer	0.0299	0.0951	CbGbCtD
Tolterodine—CYP2D6—Erlotinib—pancreatic cancer	0.0254	0.0809	CbGbCtD
Tolterodine—CYP2C9—Fluorouracil—pancreatic cancer	0.0241	0.0767	CbGbCtD
Tolterodine—CYP3A4—Tamoxifen—pancreatic cancer	0.019	0.0605	CbGbCtD
Tolterodine—CYP3A4—Erlotinib—pancreatic cancer	0.0162	0.0514	CbGbCtD
Tolterodine—CYP3A4—Irinotecan—pancreatic cancer	0.0146	0.0464	CbGbCtD
Tolterodine—CYP2D6—Doxorubicin—pancreatic cancer	0.0126	0.0399	CbGbCtD
Tolterodine—CYP3A4—Docetaxel—pancreatic cancer	0.0107	0.034	CbGbCtD
Tolterodine—CYP3A4—Sunitinib—pancreatic cancer	0.0107	0.0339	CbGbCtD
Tolterodine—CYP3A4—Doxorubicin—pancreatic cancer	0.00798	0.0254	CbGbCtD
Tolterodine—Influenza-like symptoms—Gemcitabine—pancreatic cancer	0.00166	0.0163	CcSEcCtD
Tolterodine—Gastrooesophageal reflux disease—Sunitinib—pancreatic cancer	0.00163	0.016	CcSEcCtD
Tolterodine—Dry eye—Erlotinib—pancreatic cancer	0.00158	0.0154	CcSEcCtD
Tolterodine—Influenza like illness—Sunitinib—pancreatic cancer	0.00143	0.0141	CcSEcCtD
Tolterodine—Influenza like illness—Gemcitabine—pancreatic cancer	0.00115	0.0113	CcSEcCtD
Tolterodine—Dry skin—Erlotinib—pancreatic cancer	0.00114	0.0111	CcSEcCtD
Tolterodine—Bronchitis—Tamoxifen—pancreatic cancer	0.00104	0.0102	CcSEcCtD
Tolterodine—Weight increased—Tamoxifen—pancreatic cancer	0.000984	0.00964	CcSEcCtD
Tolterodine—Dry skin—Sunitinib—pancreatic cancer	0.000983	0.00963	CcSEcCtD
Tolterodine—Disorientation—Fluorouracil—pancreatic cancer	0.000945	0.00926	CcSEcCtD
Tolterodine—Urinary tract infection—Tamoxifen—pancreatic cancer	0.000938	0.00918	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Irinotecan—pancreatic cancer	0.000912	0.00894	CcSEcCtD
Tolterodine—Sinusitis—Tamoxifen—pancreatic cancer	0.000905	0.00886	CcSEcCtD
Tolterodine—Bronchitis—Sunitinib—pancreatic cancer	0.000891	0.00873	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Gemcitabine—pancreatic cancer	0.000889	0.00871	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Sunitinib—pancreatic cancer	0.000861	0.00844	CcSEcCtD
Tolterodine—Oedema peripheral—Tamoxifen—pancreatic cancer	0.000853	0.00836	CcSEcCtD
Tolterodine—Visual impairment—Tamoxifen—pancreatic cancer	0.000834	0.00817	CcSEcCtD
Tolterodine—Influenza like illness—Docetaxel—pancreatic cancer	0.000817	0.008	CcSEcCtD
Tolterodine—Flushing—Tamoxifen—pancreatic cancer	0.000804	0.00787	CcSEcCtD
Tolterodine—Urinary tract infection—Sunitinib—pancreatic cancer	0.000803	0.00787	CcSEcCtD
Tolterodine—Dry skin—Fluorouracil—pancreatic cancer	0.000775	0.00759	CcSEcCtD
Tolterodine—Flatulence—Erlotinib—pancreatic cancer	0.000735	0.0072	CcSEcCtD
Tolterodine—Oedema peripheral—Sunitinib—pancreatic cancer	0.000731	0.00716	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Irinotecan—pancreatic cancer	0.000709	0.00695	CcSEcCtD
Tolterodine—Angioedema—Tamoxifen—pancreatic cancer	0.000689	0.00675	CcSEcCtD
Tolterodine—Flushing—Sunitinib—pancreatic cancer	0.000688	0.00674	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Fluorouracil—pancreatic cancer	0.000679	0.00666	CcSEcCtD
Tolterodine—Chest pain—Tamoxifen—pancreatic cancer	0.000642	0.00629	CcSEcCtD
Tolterodine—Arthralgia—Tamoxifen—pancreatic cancer	0.000642	0.00629	CcSEcCtD
Tolterodine—Anxiety—Tamoxifen—pancreatic cancer	0.000639	0.00626	CcSEcCtD
Tolterodine—Flatulence—Sunitinib—pancreatic cancer	0.000636	0.00623	CcSEcCtD
Tolterodine—Arthralgia—Erlotinib—pancreatic cancer	0.000635	0.00622	CcSEcCtD
Tolterodine—Chest pain—Erlotinib—pancreatic cancer	0.000635	0.00622	CcSEcCtD
Tolterodine—Urinary tract infection—Fluorouracil—pancreatic cancer	0.000633	0.00621	CcSEcCtD
Tolterodine—Anxiety—Erlotinib—pancreatic cancer	0.000633	0.0062	CcSEcCtD
Tolterodine—Dry mouth—Tamoxifen—pancreatic cancer	0.000628	0.00615	CcSEcCtD
Tolterodine—Oedema—Tamoxifen—pancreatic cancer	0.000615	0.00603	CcSEcCtD
Tolterodine—Sinusitis—Fluorouracil—pancreatic cancer	0.000611	0.00599	CcSEcCtD
Tolterodine—Infection—Tamoxifen—pancreatic cancer	0.000611	0.00599	CcSEcCtD
Tolterodine—Oedema—Erlotinib—pancreatic cancer	0.000609	0.00596	CcSEcCtD
Tolterodine—Infection—Erlotinib—pancreatic cancer	0.000605	0.00592	CcSEcCtD
Tolterodine—Angioedema—Sunitinib—pancreatic cancer	0.00059	0.00578	CcSEcCtD
Tolterodine—Visual impairment—Irinotecan—pancreatic cancer	0.000589	0.00577	CcSEcCtD
Tolterodine—Oedema peripheral—Gemcitabine—pancreatic cancer	0.000586	0.00574	CcSEcCtD
Tolterodine—Flushing—Irinotecan—pancreatic cancer	0.000567	0.00555	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Tamoxifen—pancreatic cancer	0.00056	0.00549	CcSEcCtD
Tolterodine—Dry skin—Docetaxel—pancreatic cancer	0.000559	0.00548	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Erlotinib—pancreatic cancer	0.000554	0.00543	CcSEcCtD
Tolterodine—Influenza like illness—Epirubicin—pancreatic cancer	0.000551	0.0054	CcSEcCtD
Tolterodine—Chest pain—Sunitinib—pancreatic cancer	0.00055	0.00538	CcSEcCtD
Tolterodine—Arthralgia—Sunitinib—pancreatic cancer	0.00055	0.00538	CcSEcCtD
Tolterodine—Dyspepsia—Tamoxifen—pancreatic cancer	0.000541	0.0053	CcSEcCtD
Tolterodine—Dry mouth—Sunitinib—pancreatic cancer	0.000537	0.00527	CcSEcCtD
Tolterodine—Dyspepsia—Erlotinib—pancreatic cancer	0.000536	0.00525	CcSEcCtD
Tolterodine—Fatigue—Tamoxifen—pancreatic cancer	0.00053	0.0052	CcSEcCtD
Tolterodine—Oedema—Sunitinib—pancreatic cancer	0.000527	0.00516	CcSEcCtD
Tolterodine—Pain—Tamoxifen—pancreatic cancer	0.000526	0.00515	CcSEcCtD
Tolterodine—Constipation—Tamoxifen—pancreatic cancer	0.000526	0.00515	CcSEcCtD
Tolterodine—Fatigue—Erlotinib—pancreatic cancer	0.000525	0.00514	CcSEcCtD
Tolterodine—Flatulence—Irinotecan—pancreatic cancer	0.000524	0.00513	CcSEcCtD
Tolterodine—Dry eye—Epirubicin—pancreatic cancer	0.000524	0.00513	CcSEcCtD
Tolterodine—Infection—Sunitinib—pancreatic cancer	0.000523	0.00513	CcSEcCtD
Tolterodine—Pain—Erlotinib—pancreatic cancer	0.00052	0.0051	CcSEcCtD
Tolterodine—Constipation—Erlotinib—pancreatic cancer	0.00052	0.0051	CcSEcCtD
Tolterodine—Influenza like illness—Doxorubicin—pancreatic cancer	0.00051	0.00499	CcSEcCtD
Tolterodine—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.000503	0.00493	CcSEcCtD
Tolterodine—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.000498	0.00488	CcSEcCtD
Tolterodine—Abnormal vision—Epirubicin—pancreatic cancer	0.000495	0.00485	CcSEcCtD
Tolterodine—Abdominal pain—Tamoxifen—pancreatic cancer	0.000486	0.00476	CcSEcCtD
Tolterodine—Dry eye—Doxorubicin—pancreatic cancer	0.000485	0.00475	CcSEcCtD
Tolterodine—Abdominal pain—Erlotinib—pancreatic cancer	0.000481	0.00471	CcSEcCtD
Tolterodine—Weight increased—Docetaxel—pancreatic cancer	0.00048	0.0047	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.00048	0.0047	CcSEcCtD
Tolterodine—Vertigo—Irinotecan—pancreatic cancer	0.000478	0.00468	CcSEcCtD
Tolterodine—Dyspepsia—Sunitinib—pancreatic cancer	0.000464	0.00454	CcSEcCtD
Tolterodine—Abnormal vision—Doxorubicin—pancreatic cancer	0.000458	0.00448	CcSEcCtD
Tolterodine—Fatigue—Sunitinib—pancreatic cancer	0.000454	0.00445	CcSEcCtD
Tolterodine—Hypersensitivity—Tamoxifen—pancreatic cancer	0.000453	0.00444	CcSEcCtD
Tolterodine—Constipation—Sunitinib—pancreatic cancer	0.000451	0.00441	CcSEcCtD
Tolterodine—Pain—Sunitinib—pancreatic cancer	0.000451	0.00441	CcSEcCtD
Tolterodine—Asthenia—Tamoxifen—pancreatic cancer	0.000441	0.00432	CcSEcCtD
Tolterodine—Chest pain—Gemcitabine—pancreatic cancer	0.000441	0.00432	CcSEcCtD
Tolterodine—Arthralgia—Gemcitabine—pancreatic cancer	0.000441	0.00432	CcSEcCtD
Tolterodine—Confusional state—Irinotecan—pancreatic cancer	0.000438	0.00429	CcSEcCtD
Tolterodine—Asthenia—Erlotinib—pancreatic cancer	0.000437	0.00428	CcSEcCtD
Tolterodine—Anaphylactic shock—Irinotecan—pancreatic cancer	0.000434	0.00425	CcSEcCtD
Tolterodine—Oedema—Irinotecan—pancreatic cancer	0.000434	0.00425	CcSEcCtD
Tolterodine—Chest pain—Fluorouracil—pancreatic cancer	0.000434	0.00425	CcSEcCtD
Tolterodine—Infection—Irinotecan—pancreatic cancer	0.000431	0.00422	CcSEcCtD
Tolterodine—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.000431	0.00422	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Epirubicin—pancreatic cancer	0.000425	0.00417	CcSEcCtD
Tolterodine—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.000423	0.00414	CcSEcCtD
Tolterodine—Oedema—Gemcitabine—pancreatic cancer	0.000423	0.00414	CcSEcCtD
Tolterodine—Diarrhoea—Tamoxifen—pancreatic cancer	0.000421	0.00412	CcSEcCtD
Tolterodine—Infection—Gemcitabine—pancreatic cancer	0.00042	0.00411	CcSEcCtD
Tolterodine—Confusional state—Fluorouracil—pancreatic cancer	0.000419	0.00411	CcSEcCtD
Tolterodine—Abdominal pain—Sunitinib—pancreatic cancer	0.000416	0.00408	CcSEcCtD
Tolterodine—Diarrhoea—Erlotinib—pancreatic cancer	0.000416	0.00408	CcSEcCtD
Tolterodine—Oedema peripheral—Docetaxel—pancreatic cancer	0.000416	0.00408	CcSEcCtD
Tolterodine—Oedema—Fluorouracil—pancreatic cancer	0.000416	0.00407	CcSEcCtD
Tolterodine—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.000416	0.00407	CcSEcCtD
Tolterodine—Infection—Fluorouracil—pancreatic cancer	0.000413	0.00405	CcSEcCtD
Tolterodine—Visual impairment—Docetaxel—pancreatic cancer	0.000407	0.00399	CcSEcCtD
Tolterodine—Dizziness—Tamoxifen—pancreatic cancer	0.000407	0.00399	CcSEcCtD
Tolterodine—Tachycardia—Fluorouracil—pancreatic cancer	0.000406	0.00397	CcSEcCtD
Tolterodine—Dizziness—Erlotinib—pancreatic cancer	0.000402	0.00394	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Doxorubicin—pancreatic cancer	0.000394	0.00386	CcSEcCtD
Tolterodine—Flushing—Docetaxel—pancreatic cancer	0.000392	0.00384	CcSEcCtD
Tolterodine—Hypersensitivity—Sunitinib—pancreatic cancer	0.000388	0.0038	CcSEcCtD
Tolterodine—Somnolence—Irinotecan—pancreatic cancer	0.000386	0.00378	CcSEcCtD
Tolterodine—Headache—Tamoxifen—pancreatic cancer	0.000385	0.00378	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000385	0.00377	CcSEcCtD
Tolterodine—Dyspepsia—Irinotecan—pancreatic cancer	0.000382	0.00374	CcSEcCtD
Tolterodine—Headache—Erlotinib—pancreatic cancer	0.000381	0.00374	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000379	0.00371	CcSEcCtD
Tolterodine—Asthenia—Sunitinib—pancreatic cancer	0.000378	0.0037	CcSEcCtD
Tolterodine—Dry skin—Epirubicin—pancreatic cancer	0.000377	0.0037	CcSEcCtD
Tolterodine—Somnolence—Gemcitabine—pancreatic cancer	0.000376	0.00368	CcSEcCtD
Tolterodine—Fatigue—Irinotecan—pancreatic cancer	0.000374	0.00367	CcSEcCtD
Tolterodine—Pain—Irinotecan—pancreatic cancer	0.000371	0.00364	CcSEcCtD
Tolterodine—Constipation—Irinotecan—pancreatic cancer	0.000371	0.00364	CcSEcCtD
Tolterodine—Somnolence—Fluorouracil—pancreatic cancer	0.00037	0.00362	CcSEcCtD
Tolterodine—Dyspepsia—Fluorouracil—pancreatic cancer	0.000366	0.00358	CcSEcCtD
Tolterodine—Fatigue—Gemcitabine—pancreatic cancer	0.000364	0.00357	CcSEcCtD
Tolterodine—Pain—Gemcitabine—pancreatic cancer	0.000362	0.00354	CcSEcCtD
Tolterodine—Constipation—Gemcitabine—pancreatic cancer	0.000362	0.00354	CcSEcCtD
Tolterodine—Diarrhoea—Sunitinib—pancreatic cancer	0.00036	0.00353	CcSEcCtD
Tolterodine—Feeling abnormal—Irinotecan—pancreatic cancer	0.000358	0.0035	CcSEcCtD
Tolterodine—Pain—Fluorouracil—pancreatic cancer	0.000355	0.00348	CcSEcCtD
Tolterodine—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000355	0.00348	CcSEcCtD
Tolterodine—Dry skin—Doxorubicin—pancreatic cancer	0.000349	0.00342	CcSEcCtD
Tolterodine—Dizziness—Sunitinib—pancreatic cancer	0.000348	0.00341	CcSEcCtD
Tolterodine—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000348	0.00341	CcSEcCtD
Tolterodine—Abdominal pain—Irinotecan—pancreatic cancer	0.000343	0.00336	CcSEcCtD
Tolterodine—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000343	0.00336	CcSEcCtD
Tolterodine—Bronchitis—Epirubicin—pancreatic cancer	0.000342	0.00335	CcSEcCtD
Tolterodine—Dysuria—Epirubicin—pancreatic cancer	0.000333	0.00326	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.000331	0.00324	CcSEcCtD
Tolterodine—Headache—Sunitinib—pancreatic cancer	0.00033	0.00323	CcSEcCtD
Tolterodine—Palpitations—Docetaxel—pancreatic cancer	0.000325	0.00318	CcSEcCtD
Tolterodine—Weight increased—Epirubicin—pancreatic cancer	0.000324	0.00317	CcSEcCtD
Tolterodine—Hypersensitivity—Irinotecan—pancreatic cancer	0.00032	0.00313	CcSEcCtD
Tolterodine—Bronchitis—Doxorubicin—pancreatic cancer	0.000317	0.0031	CcSEcCtD
Tolterodine—Arthralgia—Docetaxel—pancreatic cancer	0.000313	0.00307	CcSEcCtD
Tolterodine—Chest pain—Docetaxel—pancreatic cancer	0.000313	0.00307	CcSEcCtD
Tolterodine—Asthenia—Irinotecan—pancreatic cancer	0.000311	0.00305	CcSEcCtD
Tolterodine—Urinary tract infection—Epirubicin—pancreatic cancer	0.000308	0.00302	CcSEcCtD
Tolterodine—Dysuria—Doxorubicin—pancreatic cancer	0.000308	0.00302	CcSEcCtD
Tolterodine—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000306	0.003	CcSEcCtD
Tolterodine—Dry mouth—Docetaxel—pancreatic cancer	0.000306	0.003	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000306	0.003	CcSEcCtD
Tolterodine—Asthenia—Gemcitabine—pancreatic cancer	0.000303	0.00297	CcSEcCtD
Tolterodine—Confusional state—Docetaxel—pancreatic cancer	0.000302	0.00296	CcSEcCtD
Tolterodine—Oedema—Docetaxel—pancreatic cancer	0.0003	0.00294	CcSEcCtD
Tolterodine—Anaphylactic shock—Docetaxel—pancreatic cancer	0.0003	0.00294	CcSEcCtD
Tolterodine—Weight increased—Doxorubicin—pancreatic cancer	0.0003	0.00294	CcSEcCtD
Tolterodine—Infection—Docetaxel—pancreatic cancer	0.000298	0.00292	CcSEcCtD
Tolterodine—Sinusitis—Epirubicin—pancreatic cancer	0.000298	0.00292	CcSEcCtD
Tolterodine—Diarrhoea—Irinotecan—pancreatic cancer	0.000297	0.00291	CcSEcCtD
Tolterodine—Tachycardia—Docetaxel—pancreatic cancer	0.000293	0.00287	CcSEcCtD
Tolterodine—Diarrhoea—Gemcitabine—pancreatic cancer	0.000289	0.00283	CcSEcCtD
Tolterodine—Dizziness—Irinotecan—pancreatic cancer	0.000287	0.00281	CcSEcCtD
Tolterodine—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000285	0.0028	CcSEcCtD
Tolterodine—Diarrhoea—Fluorouracil—pancreatic cancer	0.000284	0.00279	CcSEcCtD
Tolterodine—Oedema peripheral—Epirubicin—pancreatic cancer	0.000281	0.00275	CcSEcCtD
Tolterodine—Sinusitis—Doxorubicin—pancreatic cancer	0.000275	0.0027	CcSEcCtD
Tolterodine—Dizziness—Fluorouracil—pancreatic cancer	0.000275	0.00269	CcSEcCtD
Tolterodine—Visual impairment—Epirubicin—pancreatic cancer	0.000274	0.00269	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000273	0.00268	CcSEcCtD
Tolterodine—Headache—Irinotecan—pancreatic cancer	0.000272	0.00266	CcSEcCtD
Tolterodine—Somnolence—Docetaxel—pancreatic cancer	0.000267	0.00261	CcSEcCtD
Tolterodine—Headache—Gemcitabine—pancreatic cancer	0.000265	0.00259	CcSEcCtD
Tolterodine—Flushing—Epirubicin—pancreatic cancer	0.000264	0.00259	CcSEcCtD
Tolterodine—Dyspepsia—Docetaxel—pancreatic cancer	0.000264	0.00259	CcSEcCtD
Tolterodine—Headache—Fluorouracil—pancreatic cancer	0.00026	0.00255	CcSEcCtD
Tolterodine—Oedema peripheral—Doxorubicin—pancreatic cancer	0.00026	0.00254	CcSEcCtD
Tolterodine—Fatigue—Docetaxel—pancreatic cancer	0.000259	0.00253	CcSEcCtD
Tolterodine—Pain—Docetaxel—pancreatic cancer	0.000257	0.00251	CcSEcCtD
Tolterodine—Constipation—Docetaxel—pancreatic cancer	0.000257	0.00251	CcSEcCtD
Tolterodine—Visual impairment—Doxorubicin—pancreatic cancer	0.000254	0.00249	CcSEcCtD
Tolterodine—Feeling abnormal—Docetaxel—pancreatic cancer	0.000247	0.00242	CcSEcCtD
Tolterodine—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000245	0.0024	CcSEcCtD
Tolterodine—Flushing—Doxorubicin—pancreatic cancer	0.000245	0.0024	CcSEcCtD
Tolterodine—Flatulence—Epirubicin—pancreatic cancer	0.000244	0.00239	CcSEcCtD
Tolterodine—Abdominal pain—Docetaxel—pancreatic cancer	0.000237	0.00232	CcSEcCtD
Tolterodine—Flatulence—Doxorubicin—pancreatic cancer	0.000226	0.00221	CcSEcCtD
Tolterodine—Vertigo—Epirubicin—pancreatic cancer	0.000223	0.00218	CcSEcCtD
Tolterodine—Hypersensitivity—Docetaxel—pancreatic cancer	0.000221	0.00217	CcSEcCtD
Tolterodine—Palpitations—Epirubicin—pancreatic cancer	0.000219	0.00215	CcSEcCtD
Tolterodine—Asthenia—Docetaxel—pancreatic cancer	0.000215	0.00211	CcSEcCtD
Tolterodine—Arthralgia—Epirubicin—pancreatic cancer	0.000211	0.00207	CcSEcCtD
Tolterodine—Chest pain—Epirubicin—pancreatic cancer	0.000211	0.00207	CcSEcCtD
Tolterodine—Anxiety—Epirubicin—pancreatic cancer	0.00021	0.00206	CcSEcCtD
Tolterodine—Dry mouth—Epirubicin—pancreatic cancer	0.000206	0.00202	CcSEcCtD
Tolterodine—Vertigo—Doxorubicin—pancreatic cancer	0.000206	0.00202	CcSEcCtD
Tolterodine—Diarrhoea—Docetaxel—pancreatic cancer	0.000205	0.00201	CcSEcCtD
Tolterodine—Confusional state—Epirubicin—pancreatic cancer	0.000204	0.002	CcSEcCtD
Tolterodine—Palpitations—Doxorubicin—pancreatic cancer	0.000203	0.00199	CcSEcCtD
Tolterodine—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000202	0.00198	CcSEcCtD
Tolterodine—Oedema—Epirubicin—pancreatic cancer	0.000202	0.00198	CcSEcCtD
Tolterodine—Infection—Epirubicin—pancreatic cancer	0.000201	0.00197	CcSEcCtD
Tolterodine—Dizziness—Docetaxel—pancreatic cancer	0.000198	0.00194	CcSEcCtD
Tolterodine—Tachycardia—Epirubicin—pancreatic cancer	0.000197	0.00193	CcSEcCtD
Tolterodine—Chest pain—Doxorubicin—pancreatic cancer	0.000195	0.00191	CcSEcCtD
Tolterodine—Arthralgia—Doxorubicin—pancreatic cancer	0.000195	0.00191	CcSEcCtD
Tolterodine—Anxiety—Doxorubicin—pancreatic cancer	0.000195	0.00191	CcSEcCtD
Tolterodine—Dry mouth—Doxorubicin—pancreatic cancer	0.000191	0.00187	CcSEcCtD
Tolterodine—Confusional state—Doxorubicin—pancreatic cancer	0.000189	0.00185	CcSEcCtD
Tolterodine—Headache—Docetaxel—pancreatic cancer	0.000188	0.00184	CcSEcCtD
Tolterodine—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000187	0.00183	CcSEcCtD
Tolterodine—Oedema—Doxorubicin—pancreatic cancer	0.000187	0.00183	CcSEcCtD
Tolterodine—Infection—Doxorubicin—pancreatic cancer	0.000186	0.00182	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000184	0.00181	CcSEcCtD
Tolterodine—Tachycardia—Doxorubicin—pancreatic cancer	0.000183	0.00179	CcSEcCtD
Tolterodine—Somnolence—Epirubicin—pancreatic cancer	0.00018	0.00176	CcSEcCtD
Tolterodine—Dyspepsia—Epirubicin—pancreatic cancer	0.000178	0.00175	CcSEcCtD
Tolterodine—Fatigue—Epirubicin—pancreatic cancer	0.000174	0.00171	CcSEcCtD
Tolterodine—Constipation—Epirubicin—pancreatic cancer	0.000173	0.0017	CcSEcCtD
Tolterodine—Pain—Epirubicin—pancreatic cancer	0.000173	0.0017	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000171	0.00167	CcSEcCtD
Tolterodine—Feeling abnormal—Epirubicin—pancreatic cancer	0.000167	0.00163	CcSEcCtD
Tolterodine—Somnolence—Doxorubicin—pancreatic cancer	0.000166	0.00163	CcSEcCtD
Tolterodine—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000165	0.00162	CcSEcCtD
Tolterodine—Dyspepsia—Doxorubicin—pancreatic cancer	0.000165	0.00161	CcSEcCtD
Tolterodine—Fatigue—Doxorubicin—pancreatic cancer	0.000161	0.00158	CcSEcCtD
Tolterodine—Pain—Doxorubicin—pancreatic cancer	0.00016	0.00157	CcSEcCtD
Tolterodine—Constipation—Doxorubicin—pancreatic cancer	0.00016	0.00157	CcSEcCtD
Tolterodine—Abdominal pain—Epirubicin—pancreatic cancer	0.00016	0.00157	CcSEcCtD
Tolterodine—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000154	0.00151	CcSEcCtD
Tolterodine—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000153	0.0015	CcSEcCtD
Tolterodine—Hypersensitivity—Epirubicin—pancreatic cancer	0.000149	0.00146	CcSEcCtD
Tolterodine—Abdominal pain—Doxorubicin—pancreatic cancer	0.000148	0.00145	CcSEcCtD
Tolterodine—Asthenia—Epirubicin—pancreatic cancer	0.000145	0.00142	CcSEcCtD
Tolterodine—Diarrhoea—Epirubicin—pancreatic cancer	0.000138	0.00136	CcSEcCtD
Tolterodine—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000138	0.00135	CcSEcCtD
Tolterodine—Asthenia—Doxorubicin—pancreatic cancer	0.000134	0.00132	CcSEcCtD
Tolterodine—Dizziness—Epirubicin—pancreatic cancer	0.000134	0.00131	CcSEcCtD
Tolterodine—Diarrhoea—Doxorubicin—pancreatic cancer	0.000128	0.00126	CcSEcCtD
Tolterodine—Headache—Epirubicin—pancreatic cancer	0.000127	0.00124	CcSEcCtD
Tolterodine—Dizziness—Doxorubicin—pancreatic cancer	0.000124	0.00121	CcSEcCtD
Tolterodine—Headache—Doxorubicin—pancreatic cancer	0.000117	0.00115	CcSEcCtD
Tolterodine—CHRM1—GPCR downstream signaling—CXCL8—pancreatic cancer	1.41e-05	0.000168	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—SMAD4—pancreatic cancer	1.4e-05	0.000167	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—CXCL8—pancreatic cancer	1.4e-05	0.000167	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CD44—pancreatic cancer	1.4e-05	0.000166	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—CXCL8—pancreatic cancer	1.39e-05	0.000165	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—HES1—pancreatic cancer	1.39e-05	0.000165	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—EGFR—pancreatic cancer	1.38e-05	0.000165	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—HES1—pancreatic cancer	1.38e-05	0.000165	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—HES1—pancreatic cancer	1.37e-05	0.000163	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.37e-05	0.000163	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.35e-05	0.000161	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—APOE—pancreatic cancer	1.35e-05	0.000161	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GCG—pancreatic cancer	1.34e-05	0.000159	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—PIK3CD—pancreatic cancer	1.34e-05	0.000159	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—PIK3CB—pancreatic cancer	1.33e-05	0.000158	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—EGFR—pancreatic cancer	1.33e-05	0.000158	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—PIK3CB—pancreatic cancer	1.32e-05	0.000158	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.32e-05	0.000158	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—PIK3CB—pancreatic cancer	1.31e-05	0.000156	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—KRAS—pancreatic cancer	1.31e-05	0.000156	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CD44—pancreatic cancer	1.28e-05	0.000153	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—PIK3CD—pancreatic cancer	1.28e-05	0.000152	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—CXCL8—pancreatic cancer	1.28e-05	0.000152	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—CXCL8—pancreatic cancer	1.27e-05	0.000152	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CD44—pancreatic cancer	1.27e-05	0.000152	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.27e-05	0.000151	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—CXCL8—pancreatic cancer	1.26e-05	0.00015	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—STK11—pancreatic cancer	1.26e-05	0.00015	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—KRAS—pancreatic cancer	1.25e-05	0.000149	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.25e-05	0.000148	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.23e-05	0.000147	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GCG—pancreatic cancer	1.23e-05	0.000147	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PIK3CG—pancreatic cancer	1.22e-05	0.000146	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GCG—pancreatic cancer	1.22e-05	0.000145	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TERT—pancreatic cancer	1.22e-05	0.000145	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TERT—pancreatic cancer	1.21e-05	0.000144	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—PIK3CA—pancreatic cancer	1.2e-05	0.000143	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TERT—pancreatic cancer	1.2e-05	0.000143	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.18e-05	0.000141	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PPARG—pancreatic cancer	1.18e-05	0.00014	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—PIK3CB—pancreatic cancer	1.16e-05	0.000139	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—HIF1A—pancreatic cancer	1.16e-05	0.000139	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GLP1R—pancreatic cancer	1.16e-05	0.000138	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TSC2—pancreatic cancer	1.16e-05	0.000138	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—HIF1A—pancreatic cancer	1.16e-05	0.000138	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—STK11—pancreatic cancer	1.16e-05	0.000138	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TSC2—pancreatic cancer	1.16e-05	0.000138	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—PIK3CA—pancreatic cancer	1.15e-05	0.000137	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—HIF1A—pancreatic cancer	1.15e-05	0.000137	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—STK11—pancreatic cancer	1.15e-05	0.000137	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TSC2—pancreatic cancer	1.15e-05	0.000136	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—DPYD—pancreatic cancer	1.14e-05	0.000136	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—APOE—pancreatic cancer	1.14e-05	0.000135	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—APOE—pancreatic cancer	1.13e-05	0.000135	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—APOE—pancreatic cancer	1.12e-05	0.000134	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CXCL8—pancreatic cancer	1.12e-05	0.000133	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—PIK3CB—pancreatic cancer	1.12e-05	0.000133	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—KDR—pancreatic cancer	1.11e-05	0.000133	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—HRAS—pancreatic cancer	1.11e-05	0.000132	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—KDR—pancreatic cancer	1.11e-05	0.000132	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—KDR—pancreatic cancer	1.1e-05	0.000131	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	1.08e-05	0.000129	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—TYMS—pancreatic cancer	1.08e-05	0.000129	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—AKT1—pancreatic cancer	1.08e-05	0.000129	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.08e-05	0.000128	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PIK3CD—pancreatic cancer	1.07e-05	0.000128	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CXCL8—pancreatic cancer	1.07e-05	0.000128	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CASP3—pancreatic cancer	1.07e-05	0.000128	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—HRAS—pancreatic cancer	1.06e-05	0.000127	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—NFKBIA—pancreatic cancer	1.06e-05	0.000126	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—NFKBIA—pancreatic cancer	1.05e-05	0.000126	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—NOTCH1—pancreatic cancer	1.05e-05	0.000125	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—NOTCH1—pancreatic cancer	1.04e-05	0.000124	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—NFKBIA—pancreatic cancer	1.04e-05	0.000124	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CCND1—pancreatic cancer	1.04e-05	0.000124	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—AKT1—pancreatic cancer	1.04e-05	0.000123	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—NOTCH1—pancreatic cancer	1.03e-05	0.000123	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CTNNB1—pancreatic cancer	1.03e-05	0.000123	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CASP3—pancreatic cancer	1.03e-05	0.000122	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PIK3CG—pancreatic cancer	1.02e-05	0.000122	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—NRAS—pancreatic cancer	1.02e-05	0.000122	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PIK3CG—pancreatic cancer	1.02e-05	0.000122	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—NRAS—pancreatic cancer	1.02e-05	0.000122	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—EGF—pancreatic cancer	1.01e-05	0.000121	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MMP9—pancreatic cancer	1.01e-05	0.000121	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PIK3CG—pancreatic cancer	1.01e-05	0.000121	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—NRAS—pancreatic cancer	1.01e-05	0.000121	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—EGF—pancreatic cancer	1.01e-05	0.00012	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—PTEN—pancreatic cancer	1.01e-05	0.00012	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—EGF—pancreatic cancer	1e-05	0.000119	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CCND1—pancreatic cancer	9.98e-06	0.000119	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—TYMS—pancreatic cancer	9.95e-06	0.000119	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CTNNB1—pancreatic cancer	9.89e-06	0.000118	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—TYMS—pancreatic cancer	9.86e-06	0.000118	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—AKT1—pancreatic cancer	9.82e-06	0.000117	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MMP9—pancreatic cancer	9.69e-06	0.000116	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—PTEN—pancreatic cancer	9.64e-06	0.000115	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—AKT1—pancreatic cancer	9.4e-06	0.000112	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PIK3CB—pancreatic cancer	9.36e-06	0.000112	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—EGFR—pancreatic cancer	9.34e-06	0.000111	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—SRC—pancreatic cancer	9.33e-06	0.000111	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—EGFR—pancreatic cancer	9.31e-06	0.000111	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PTGS2—pancreatic cancer	9.27e-06	0.000111	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—EGFR—pancreatic cancer	9.22e-06	0.00011	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—VEGFA—pancreatic cancer	9.09e-06	0.000108	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PIK3CD—pancreatic cancer	9.01e-06	0.000107	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—STAT3—pancreatic cancer	9e-06	0.000107	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PIK3CD—pancreatic cancer	8.98e-06	0.000107	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—NRAS—pancreatic cancer	8.98e-06	0.000107	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—SRC—pancreatic cancer	8.94e-06	0.000106	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.92e-06	0.000106	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.89e-06	0.000106	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PIK3CD—pancreatic cancer	8.89e-06	0.000106	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—KRAS—pancreatic cancer	8.82e-06	0.000105	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.81e-06	0.000105	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—APOE—pancreatic cancer	8.8e-06	0.000105	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—KRAS—pancreatic cancer	8.79e-06	0.000105	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—KRAS—pancreatic cancer	8.71e-06	0.000104	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—VEGFA—pancreatic cancer	8.7e-06	0.000104	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—STAT3—pancreatic cancer	8.62e-06	0.000103	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—NRAS—pancreatic cancer	8.6e-06	0.000102	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CD44—pancreatic cancer	8.39e-06	0.0001	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MYC—pancreatic cancer	8.36e-06	9.97e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—TGFB1—pancreatic cancer	8.34e-06	9.94e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	8.33e-06	9.93e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—EGFR—pancreatic cancer	8.18e-06	9.75e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—PIK3CA—pancreatic cancer	8.1e-06	9.66e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—APOE—pancreatic cancer	8.09e-06	9.64e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PTEN—pancreatic cancer	8.09e-06	9.64e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—PIK3CA—pancreatic cancer	8.08e-06	9.63e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GCG—pancreatic cancer	8.04e-06	9.59e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—APOE—pancreatic cancer	8.02e-06	9.56e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MYC—pancreatic cancer	8.01e-06	9.54e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—PIK3CA—pancreatic cancer	8e-06	9.53e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TGFB1—pancreatic cancer	7.99e-06	9.52e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	7.94e-06	9.46e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PIK3CB—pancreatic cancer	7.85e-06	9.36e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—EGFR—pancreatic cancer	7.83e-06	9.33e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PIK3CB—pancreatic cancer	7.83e-06	9.33e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PIK3CB—pancreatic cancer	7.75e-06	9.24e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—KRAS—pancreatic cancer	7.73e-06	9.21e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PPARG—pancreatic cancer	7.66e-06	9.13e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	7.59e-06	9.05e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—STK11—pancreatic cancer	7.56e-06	9.01e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CXCL8—pancreatic cancer	7.54e-06	8.99e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CXCL8—pancreatic cancer	7.52e-06	8.96e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—HRAS—pancreatic cancer	7.5e-06	8.93e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—HRAS—pancreatic cancer	7.47e-06	8.9e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CXCL8—pancreatic cancer	7.45e-06	8.88e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—HRAS—pancreatic cancer	7.4e-06	8.82e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—KRAS—pancreatic cancer	7.4e-06	8.82e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	7.3e-06	8.7e-05	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—AKT1—pancreatic cancer	7.29e-06	8.69e-05	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—AKT1—pancreatic cancer	7.27e-06	8.66e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	7.24e-06	8.63e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CASP3—pancreatic cancer	7.22e-06	8.61e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CASP3—pancreatic cancer	7.2e-06	8.58e-05	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—AKT1—pancreatic cancer	7.19e-06	8.57e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CASP3—pancreatic cancer	7.13e-06	8.5e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—PIK3CA—pancreatic cancer	7.1e-06	8.46e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PPARG—pancreatic cancer	7.05e-06	8.4e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CCND1—pancreatic cancer	7.03e-06	8.38e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CCND1—pancreatic cancer	7.01e-06	8.35e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PPARG—pancreatic cancer	6.99e-06	8.33e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	6.98e-06	8.32e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CTNNB1—pancreatic cancer	6.96e-06	8.3e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CCND1—pancreatic cancer	6.94e-06	8.27e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CTNNB1—pancreatic cancer	6.94e-06	8.27e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CTNNB1—pancreatic cancer	6.87e-06	8.19e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—TP53—pancreatic cancer	6.87e-06	8.18e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MMP9—pancreatic cancer	6.82e-06	8.13e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MMP9—pancreatic cancer	6.8e-06	8.11e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—PIK3CA—pancreatic cancer	6.8e-06	8.1e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PTEN—pancreatic cancer	6.78e-06	8.09e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PTEN—pancreatic cancer	6.76e-06	8.06e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MMP9—pancreatic cancer	6.74e-06	8.03e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PTEN—pancreatic cancer	6.7e-06	7.98e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—AKT1—pancreatic cancer	6.62e-06	7.89e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—AKT1—pancreatic cancer	6.6e-06	7.86e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TP53—pancreatic cancer	6.58e-06	7.84e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—HRAS—pancreatic cancer	6.57e-06	7.83e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—AKT1—pancreatic cancer	6.53e-06	7.79e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—TYMS—pancreatic cancer	6.51e-06	7.75e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	6.42e-06	7.65e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	6.37e-06	7.59e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—SRC—pancreatic cancer	6.29e-06	7.5e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—HRAS—pancreatic cancer	6.29e-06	7.49e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—SRC—pancreatic cancer	6.27e-06	7.47e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—SRC—pancreatic cancer	6.21e-06	7.4e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—VEGFA—pancreatic cancer	6.13e-06	7.3e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—VEGFA—pancreatic cancer	6.11e-06	7.28e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	6.08e-06	7.25e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—STAT3—pancreatic cancer	6.07e-06	7.23e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—NRAS—pancreatic cancer	6.05e-06	7.21e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—VEGFA—pancreatic cancer	6.05e-06	7.21e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—STAT3—pancreatic cancer	6.05e-06	7.21e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—NRAS—pancreatic cancer	6.03e-06	7.19e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PTGS2—pancreatic cancer	6.03e-06	7.19e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—STAT3—pancreatic cancer	5.99e-06	7.14e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—NRAS—pancreatic cancer	5.97e-06	7.12e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—AKT1—pancreatic cancer	5.8e-06	6.91e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PIK3CA—pancreatic cancer	5.71e-06	6.8e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MYC—pancreatic cancer	5.64e-06	6.72e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TGFB1—pancreatic cancer	5.62e-06	6.7e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MYC—pancreatic cancer	5.62e-06	6.7e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TGFB1—pancreatic cancer	5.61e-06	6.68e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	5.6e-06	6.67e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MYC—pancreatic cancer	5.57e-06	6.63e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—AKT1—pancreatic cancer	5.55e-06	6.62e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TGFB1—pancreatic cancer	5.55e-06	6.62e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	5.55e-06	6.61e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PTGS2—pancreatic cancer	5.55e-06	6.61e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—EGFR—pancreatic cancer	5.51e-06	6.57e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PTGS2—pancreatic cancer	5.5e-06	6.55e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—EGFR—pancreatic cancer	5.5e-06	6.55e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—EGFR—pancreatic cancer	5.44e-06	6.49e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—APOE—pancreatic cancer	5.29e-06	6.31e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PTEN—pancreatic cancer	5.26e-06	6.27e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—KRAS—pancreatic cancer	5.21e-06	6.21e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—KRAS—pancreatic cancer	5.19e-06	6.19e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—KRAS—pancreatic cancer	5.14e-06	6.13e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PTEN—pancreatic cancer	4.84e-06	5.76e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PTEN—pancreatic cancer	4.79e-06	5.71e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PIK3CA—pancreatic cancer	4.79e-06	5.7e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	4.78e-06	5.69e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PIK3CA—pancreatic cancer	4.77e-06	5.69e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PIK3CA—pancreatic cancer	4.72e-06	5.63e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—AKT1—pancreatic cancer	4.66e-06	5.55e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TP53—pancreatic cancer	4.63e-06	5.52e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TP53—pancreatic cancer	4.62e-06	5.5e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PPARG—pancreatic cancer	4.61e-06	5.49e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TP53—pancreatic cancer	4.57e-06	5.45e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—HRAS—pancreatic cancer	4.43e-06	5.28e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—HRAS—pancreatic cancer	4.41e-06	5.26e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—HRAS—pancreatic cancer	4.37e-06	5.21e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	4.2e-06	5e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—AKT1—pancreatic cancer	3.91e-06	4.66e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—AKT1—pancreatic cancer	3.9e-06	4.64e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—AKT1—pancreatic cancer	3.86e-06	4.6e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	3.71e-06	4.42e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	3.66e-06	4.36e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PTGS2—pancreatic cancer	3.63e-06	4.32e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	3.41e-06	4.07e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	3.38e-06	4.03e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PTEN—pancreatic cancer	3.16e-06	3.77e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—AKT1—pancreatic cancer	3.03e-06	3.61e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—AKT1—pancreatic cancer	2.79e-06	3.32e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—AKT1—pancreatic cancer	2.76e-06	3.29e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	2.23e-06	2.66e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.82e-06	2.17e-05	CbGpPWpGaD
